US 6,284,776 B1Granted

Method for treating diseased-related or drug-induced dyskinesias

OwnerLeonard T. Meltzerinventor

Life of this patent

Estimating the term…

Abstract

Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom.

Claims7

Dependent claims

A method for treating dyskinesias, said method comprising administering to a human suffering therefrom a therapeutically effective amount of a NR1A/2B site-selective NMDA receptor antagonist compound.

Dependencies are inferred from the claim text.

Facts

Application: 09/485,348Filed 7 Feb 2000 · us provisional application
Priority: 24 Oct 1997
Granted: 4 Sep 2001
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/453
Containing further heterocyclic ring systems: containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine
A61K 31/451
Non condensed piperidines, e.g. piperocaine: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine,…

Family

Application60/063,156Us provisional application · filed 24 Oct 1997
US 6,284,776 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results